Lidocaine attenuation testing: An in vivo investigation of putative LQT3-associated variants in the SCN5A-encoded sodium channel.

ABSTRACT:

Background

Long QT syndrome type 3 (LQT3) accounts for 5%-10% of long QT syndrome and results from gain-of-function mutations in the SCN5A-encoded sodium channel. Approximately 2% of healthy individuals host rare SCN5A variants of uncertain significance (VUS). Distinction of true LQT3-causative mutations from background genetic noise is essential.

Objective

The purpose of this study was to assess the use of the lidocaine attenuation test (LAT) in evaluating patients with possible LQT3.

Methods

We reviewed the LAT results and medical records for 25 patients with a possible LQT3-associated SCN5A variant. The LAT involved a loading dose of 1 mg/kg of intravenous lidocaine followed by continuous infusion at 50 μg/(kg⋅min) for 20 minutes. If the corrected QT interval short

SUBMITTER: Anderson HN 

PROVIDER: S-EPMC6590893 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature